Position in CELC
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$2,085,390
+$1,308,440 QoQ
Shares Held
19,933
+192.8% QoQ
Ownership
0.041%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#119
of 273 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HARBOR CAPITAL ADVISORS, INC. holds $28,134,645 across 28 Biotechnology names. CELC ranks #5 (7.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KYMR |
Kymera Therapeutics, Inc.
|
36,368 | $4,170,318 | |
| 2 | VCEL |
Vericel Corp
|
72,852 | $3,241,185 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
36,977 | $2,894,189 | |
| 4 | RARE |
Ultragenyx Pharmaceutical Inc.
|
72,316 | $2,414,631 | |
| 5 | CELC |
Celcuity Inc.
This page
|
19,933 | $2,085,390 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
29,612 | $1,863,779 | |
| 7 | AGIO |
Agios Pharmaceuticals, Inc.
|
46,550 | $1,727,470 | |
| 8 | SRPT |
Sarepta Therapeutics, Inc.
|
92,669 | $1,665,261 |
All Filings in CELC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,085,390 | 19,933 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $776,950 | 6,807 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $627,663 | 6,293 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $398,707 | 8,071 | Shares | Sole | 2025-10-15 | |
| No filing history on record for this holder in this stock. | ||||||